Poland· PL-100505993

Iqirvo

A elafibranor product containing elafibranor, registered in Poland by Ipsen Pharma. The same ATC class is registered in 12 of our 19 countries.

ATC A05AX06

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about elafibranorAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Elafibranor is registered in 12 of 19 countries.

Countries holding a registration under ATC A05AX06 (elafibranor), each read from that country’s own register.

This record: Poland, from URPL (Poland)
8 of them publish a price we can compare per daily dose

Search elafibranor products by name

Elafibranor · ATC A05AX06

12 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)

Active substance: elafibranor
Manufacturer: Ipsen Pharma
Country: Poland (PL)
ATC code: A05AX06
ATC class: Elafibranor
Defined daily dose: 80 mg, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 1

gtin
03582180003141

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Elafibranor in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All elafibranor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Iqirvo
Liechtenstein · Iqirvo
Norway · Iqirvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/494f67ff-678f-463b-a2b5-3a11e1b21018
GET /v1/drugs/494f67ff-678f-463b-a2b5-3a11e1b21018?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "80 mg",
  "packaging": "03582180003141 ¦ Rp ¦ EU/1/24/1855/001 ¦ 158257\n30 tabl.\n¦ UR/Z/4b/135/25 - 03582180003141 ¦ UR/Z/4b/090/25 - 03582180003141 ¦ UR/Z/4b/001/25 - 03582180003141 ¦ UR/Z/4b/023/26 - 03582180003141 ¦ UR/Z/4b/166/26 - 03582180003141",
  "substance": "elafibranor 80 mg",
  "common_name": "elafibranor",
  "pl_product_id": "100505993",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

API reference MCP server Plans

See everything about elafibranor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console